Advancements and challenges in CAR T cell therapy in autoimmune diseases

• Published in: Nature reviews. Rheumatology Vol. 20; no. 9; pp. 531 - 544
• Main Authors: Schett, Georg, Müller, Fabian, Taubmann, Jule, Mackensen, Andreas, Wang, Wei, Furie, Rich A, Gold, Ralf, Haghikia, Aiden, Merkel, Peter A, Caricchio, Roberto, D'Agostino, Maria-Antonietta, Locatelli, Franco, June, Carl H, Mougiakakos, Dimitrios
• Format: Journal Article
• Language: English
• Published: United States Nature Publishing Group 01.09.2024
• Subjects: Antigens; Autoimmune diseases; CD19 antigen; Cell lineage; Cell therapy; Chimeric antigen receptors; Immune response; Inflammatory diseases; Lymphocytes; Lymphocytes B; Lymphocytes T; Malignancy; Multiple sclerosis; Myasthenia gravis; Myopathy; Neuromuscular junctions; Neuromyelitis; Patients; Plasma cells; Recovery of function; Remission; Systemic lupus erythematosus; Systemic sclerosis

Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients with relapsed or refractory B cell malignancies. In addition, the administration of genetically modified T ce...